Three airborne or aerosol-borne infections with very different epidemiology: pertussis (humans only, highly contagious, adults infect infants), meningococcal disease (healthy nasopharyngeal carriers are the main source) and legionellosis (an environmental sapronosis: water systems, never person to person).
The key to the epidemiological answer is the chain: agent, source, route, susceptible host. Pertussis and meningococcus are controlled by vaccination plus contact chemoprophylaxis; Legionella is controlled by water-system management and finding the source.
The key to control in the focus: notify at once, list the close contacts, give chemoprophylaxis as early as possible (ideally within 24 hours) to meningococcal contacts and azithromycin to pertussis contacts, and sample the water in a Legionella cluster. Clinical picture and treatment of cases: topics 18 and 19.
Pertussis (whooping cough)
Agent, source and route
Agent: Bordetella pertussis, a small Gram-negative coccobacillus; virulence factors include pertussis toxin and filamentous haemagglutinin. B. parapertussis causes a milder, similar illness and is not covered by the vaccine.
Reservoir: humans only; there is no chronic carrier state and no environmental reservoir.
Source: a patient, most infectious in the catarrhal stage and in the first two weeks of cough. Adolescents and adults with a mild, unrecognised cough are the usual source of infection for infants.
Transmission: respiratory droplets in close contact. It is one of the most contagious diseases: household attack rate up to 80-90% in susceptible contacts, basic reproduction number roughly 12-17.
Incubation: usually 7-10 days (range 5-21). Contagious from the catarrhal stage until about 3 weeks after cough onset if untreated, or until 5 days of effective azithromycin.
Immunity, pattern and burden
Protection after disease or vaccine wanes (a few years after vaccine, longer after natural infection), so adolescents and adults are susceptible again and re-infected.
Epidemic peaks recur every 3-5 years; many countries with high coverage still see resurgence, partly because acellular vaccines protect less durably than whole-cell ones.
Severe disease and almost all deaths occur in infants younger than 3 months, who are too young to have completed the primary series.
No strong seasonality in temperate countries (some late-summer rise). Reporting is incomplete because adult disease is under-diagnosed.
Prevention
Routine: acellular pertussis component (DTaP) in the primary series in infancy, with boosters, under the Bulgarian immunisation calendar (Ordinance No. 15 of 2005, as amended); exact ages are in the current ordinance.